Page 8 - Juvenescence Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Juvenescence ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Juvenescence Ltd Today - Breaking & Trending Today

FastForward Innovations Limited (LSE:FFWD) | RNS | FastForward Inn Ltd

FastForward Innovations Limited (LSE:FFWD) | RNS | FastForward Inn Ltd
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

New Zealand , New South Wales , United Kingdom , City Of , Roland Cornish , James Biddle , Isabella Pierre , Damon Heath , Beth Melluish , Rebekah Hall , Ted Mcdermott , French Agency For The Safety Of Medicines , Globalive Technology Inc , Life Sciences Plc , University Of Sydney , Yooma Wellness Inc , Investee Company , Turkish Airlines Euroleague , Canadian Securities Exchange , Fastforward Innovations Ltd , Juvenescence Ltd , York Stock Exchange , London Stock Exchange , Beaumont Cornish , Shard Capital Partners , Kanabo Group Plc ,

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing
News provided by
Share this article
Share this article
PITTSBURGH, Dec. 30, 2020 /PRNewswire/ LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application. Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD). ....

United States , Jim Mellon , Declan Doogan , Michael Hufford , Sergey Young , Gregory Bailey , Longevity Vision Fund , Lygenesis Inc , Juvenescence Ltd , Drug Administration , Investigational New Drug , Longevity Vision , Vision Fund , Innovation Board , Age Reversal , ஒன்றுபட்டது மாநிலங்களில் , ஜிம் மெலந் , டெக்லான் தூகண் , மைக்கேல் ஹஃபோர்ட் , செர்ஜி இளம் , கிரெகொரி பெய்லி , நீண்ட ஆயுள் பார்வை நிதி , நீண்ட ஆயுள் பார்வை , பார்வை நிதி , கண்டுபிடிப்பு பலகை , வாழ்நாள் தலைகீழ் ,

Investegate |Evgen Pharma PLC Announcements | Evgen Pharma PLC: Half-year Report

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months ended 30 September 2020.

·
Dr Huw Jones appointed as Chief Executive Officer
·
Completion of first out-licensing deal with Juvenescence for use of Sulforadex® technology in non-pharmaceutical markets. Up to $10.5m receivable in milestones with royalties on sales
·
Phase IIb/III trial using SFX-01 for
acute respiratory distress syndrome (
ARDS ) including COVID-19 patients sponsored by Dundee University, with grant funding from LifeArc; the STAR trial (
SFX-01 treatment for acute respiratory infections)
·
Patient recruitment commenced in STAR trial post the period end with data potent ....

United Kingdom , Borough Of Cheshire East , City Of , United Kingdom General , Evgen Pharmaplcwww , Barry Clarehuw Jones , Huw Jones , Evgen Pharma , Brownlow Hill , Geoff Nash Teddy Whiley , Richard Moulson , Paul Mcmanus Anna Dunphy , Juvenescence Ltd , Company Share Capital , International Financial Reporting Standards , London Stock Exchange , University Of Manchester , Market Of The London Stock Exchange , University Of Dundee , Liverpool Science Park Innovation Centre , Registrar Of Companies , European Union , Cancer Research United Kingdom Manchester Institute , Dundee University , Chief Executive , Chief Executive Officer ,